Multi-center, randomized clinical trial to study the impact of in-hospital guidance for acutely decompensated heart failure treatment by predefined NT-proBNP targets (>30% reduction in NT-proBNP during admission) on the reduction of readmission rates and mortality - Prima II

Academisch Medisch Centrum0 个研究点目标入组 362 人开始时间: 待定最近更新: 2024年5月6日

适应症

试验速览

暂无简介。

•1. Hospital admission because of clinically validated acutely decompensated heart failure.
•2. Elevated NT-proBNP levels *1700 ng/L (*200 pmol/L) on hospital admission.
•3. Written informed consent to participate in this study prior to any study procedures

•1. Severe Chronic Obstructive Pulmonary Disease (COPD) with FEV<1l/min.
•2. Pulmonary embolism within 1 month prior to admission and pulmonary hypertension not caused by left ventricle dysfunction (LVD).
•3. Patients undergoing Continue Ambulant Peritoneal Dialysis (CAPD)/ Haemodialysis patients.
•4. Patients with planned Coronary Artery Bypass Grafting (CABG), Percutaneous Coronary Intervention (PCI), Cardiac Resynchronization Therapy (CRT) and/or valvular surgery before admission (until one day before admission).
•5. Patients with planned Coronary Artery Bypass Grafting (CABG), Percutaneous Coronary Intervention (PCI), Cardiac Resynchronization Therapy (CRT) and/or valvular surgery during admission until the moment of randomization
•6. Patient with a history of ST-segment-Elevated Myocardial Infarction (STEMI), CABG, PCI, CRT and/or valvular surgery within 1 month prior to admission.
•7. Patients in cardiogenic shock at admission requiring invasive treatment.
•8. Signed informed consent for any current interventional study.
•9. Presence of severe non-cardiac related life-threatening disease before inclusion with an expected survival of less than 6 months after inclusion.
•10. Mental of physical status not allowing written informed consent.
•11. Unwillingness to give informed consent.
•12. Circumstances that prevent follow-up (no permanent home address, transient, etc.)

发起方